Do you put weight back on after stopping Wegovy?

Weight regain after stopping Wegovy is documented in clinical trials: the STEP 1 extension study found participants regained most of the lost weight within 12 months of discontinuation.
Regain happens because Wegovy works on appetite-regulating hormones that return to their pre-treatment state once the medicine leaves your system.
Lifestyle habits built during treatment (eating patterns, activity levels) can slow the pace of regain but rarely prevent it entirely without ongoing clinical support.
NICE recommends semaglutide for a maximum of two years within specialist services; what happens after that is a conversation between you and your prescriber, not a given.

Most people do regain some weight after stopping Wegovy. Clinical trial data show that, on average, roughly two-thirds of the weight lost during treatment returns within a year of discontinuing semaglutide — because the medicine works on biological pathways that remain active only while you're taking it. That said, the picture is more nuanced than a simple yes or no, and how much comes back varies considerably from person to person. Wegovy (semaglutide) is a prescription-only medicine; a prescriber assesses whether it is suitable for you and for how long treatment should continue.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The biology, the trial data, and what you can realistically do about it

Why does weight tend to come back when you stop?

Semaglutide (the active ingredient in Wegovy) works by mimicking a gut hormone called GLP-1. It slows gastric emptying, signals fullness to the brain, and dials down appetite. While you are taking it, your body operates under that hormonal influence. Stop the injections and the influence stops too. Hunger signals tend to recover to roughly where they were before you started, and so does the drive to eat.

This isn't a personal failing. Obesity is a chronic condition with a strong biological basis, and the hormonal environment that made it hard to lose weight in the first place reasserts itself once the medicine is gone. The NHS describes weight management medicines as treatments for an ongoing condition rather than short-term fixes, which is why clinical guidance emphasises long-term support alongside any prescription. You can read more about how semaglutide works on the semaglutide treatment overview.

The practical implication is that the question of stopping is one worth raising with your prescriber well before you plan to do it, not on the day you run out of pens.

What did the trials actually find?

The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. A follow-up extension then tracked what happened after participants stopped treatment and returned to lifestyle advice alone. Within 12 months of stopping, most of that loss had reversed, and if you want a detailed look at the pattern, our page on whether you put weight back on after stopping Wegovy goes through the evidence in full.

That is a striking figure, and it matters to anyone planning their treatment. It doesn't mean treatment is pointless: the health benefits gained during treatment are real, and the trajectory after stopping is not the same for everyone. People who made substantial changes to eating habits and physical activity during treatment tended to fare better. But the data are clear that the medicine is doing significant work, and that work stops when the medicine does.

If you want to see how the weight-loss curve typically looks over the course of treatment, the Wegovy weight-loss graph page walks through what the STEP 1 data show week by week.

Does stopping always mean full regain?

Not always, and not immediately. The speed and extent of regain depend on several factors: how long you were on treatment, what dose you reached, how your lifestyle shifted during the programme, and your individual biology. Some people maintain a meaningful portion of their loss for longer, particularly if they stayed active and kept dietary habits in place, and our page looking at whether you gain weight back after Wegovy explores what influences that variation.

There is also an emerging conversation about structured withdrawal (stepping down doses gradually rather than stopping abruptly) though evidence on whether this reduces regain is still limited. Your prescriber is the right person to discuss this with, and the practical tips page covers some of the lifestyle strategies people find useful during and after treatment.

One thing worth noting is that partial maintenance is still a health gain. Even regaining half the weight lost leaves you in a better position than you started. The goal isn't always to hold a specific number on the scale permanently.

What are the options if you want to continue or restart?

NICE's appraisal of semaglutide (NICE TA875) recommends it for up to two years within specialist weight management services on the NHS. Private prescribing follows the licensed indication rather than that time cap, but every continuation still requires clinical review. At nume (at our pharmacy) there are no automatic renewals; a prescriber re-reviews your case before every repeat, so you are always making an active clinical decision rather than defaulting.

Some people who stop and regain do restart treatment, and if you are considering that route it is worth reading about putting weight on with Wegovy to understand how the medicine interacts with weight over time. Others move on to a different approach, including tirzepatide, which you can compare on the weight-loss treatment overview. Neither path is wrong. The right one depends on your health picture, your goals, and what a prescriber thinks is appropriate for you at that point.

If you are weighing up what continuing treatment might look like, or want to understand whether you'd be suitable to restart, speaking to a prescriber is the practical next step. You can start a free consultation with our clinical team and get a same-day review from a GPhC-registered prescriber. If treatment is appropriate, your medication arrives via tracked DPD delivery, in plain, unbranded packaging, the next working day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions